Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 20,890,253	$ 33,794,672
Receivable due from collaboration agreement	1,812,975	1,628,703
Research and development tax incentive receivable	994,549	966,646
Prepaid assets and other current assets	1,483,953	2,447,930
Total current assets	25,181,730	38,837,951
Operating lease right-of-use asset, net	232,138
Property and equipment, net	2,332,254	1,859,860
Other assets	167,077
Total assets	27,913,199	40,697,811
Current liabilities:
Accounts payable	3,480,461	1,493,842
Accrued compensation		416,910
Deferred research grant revenue	268,000	50,000
Current portion of operating lease liability	79,050
Total current liabilities	3,827,511	1,960,752
Operating lease liability, net of current portion	146,188
Total liabilities	3,973,699	1,960,752
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 45,000,000 shares authorized; 25,373,818 and 25,371,781 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	25,374	25,372
Additional paid-in capital	106,461,934	104,078,968
Accumulated other comprehensive loss	(107,121)	(48,921)
Accumulated deficit	(82,440,687)	(65,318,360)
Total stockholders’ equity	23,939,500	38,737,059
Total liabilities and stockholders’ equity	$ 27,913,199	$ 40,697,811